| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/20/2001 | DE10012549A1 New heterocyclic-substituted dihydropyrimidine derivatives useful for treatment of viral infections, especially hepatitis B infections |
| 09/20/2001 | CA2403679A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403358A1 Antiviral therapy |
| 09/20/2001 | CA2403241A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | CA2403084A1 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" |
| 09/20/2001 | CA2403062A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402935A1 Adjuvant for vaccines |
| 09/20/2001 | CA2402898A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | CA2402891A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402807A1 Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria |
| 09/20/2001 | CA2402718A1 Fish vaccine against piscirickettsia salmonis |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |
| 09/20/2001 | CA2402312A1 Treatment of herpes infection using immunomodulatory polynucleotide sequences |
| 09/20/2001 | CA2402294A1 Immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | CA2402259A1 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | CA2402250A1 Immunomodulatory polynucleotide sequences for use in suppressing hepatitis virus infection |
| 09/20/2001 | CA2402237A1 Improved methods to isolate, identify, quantify, and propagate chicken infectious anemia virus and high titer vaccine |
| 09/20/2001 | CA2402025A1 Nystatin formulation having reduced toxicity |
| 09/20/2001 | CA2402014A1 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | CA2401273A1 Il-17 receptor like molecules and uses thereof |
| 09/20/2001 | CA2400370A1 Nucleoside compounds and uses thereof |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/20/2001 | CA2400043A1 Antiviral prodrugs |
| 09/19/2001 | EP1134289A1 Method for screening cd14 agonist or antagonist |
| 09/19/2001 | EP1134229A2 Method of preparing clarithromycin of form II crystals |
| 09/19/2001 | EP1134222A1 IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM |
| 09/19/2001 | EP1134219A1 Cycloalkyl-substituted aminomethylpyrrolidine derivatives |
| 09/19/2001 | EP1134216A1 Anti-drug resistant strain agents and antichlamydia agents |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133979A2 Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon |
| 09/19/2001 | EP1133692A1 Methods of identifying viral therapeutics |
| 09/19/2001 | EP1133561A2 Protein fragments for use in protein targeting |
| 09/19/2001 | EP1133500A1 Organophosphorous compounds and the use thereof |
| 09/19/2001 | EP1133497A1 Crystal modification b of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1,4- dihydro-4- oxo-3-quinoline carboxylic acid |
| 09/19/2001 | EP1133496A1 Crystal modification a of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro- 4-oxo-3- quinoline carboxylic acid |
| 09/19/2001 | EP1133495A1 Semi-hydrochloride of 8-cyan-1- cyclopropyl -7-(1s,6s-2 ,8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro -4-oxo-3- quinoline carboxylic acid |
| 09/19/2001 | EP1133494A1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 09/19/2001 | EP1133493A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
| 09/19/2001 | EP1133491A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | EP1133487A1 Scavenger compounds |
| 09/19/2001 | EP1133477A1 Substituted benzimidazoles and their use as parp inhibitors |
| 09/19/2001 | EP1133319A1 Photosensitizer conjugates for targeting intracellular pathogens |
| 09/19/2001 | EP1133302A2 Use of phosphonoformic acid derivatives for treating infections |
| 09/19/2001 | EP1133298A1 Compositions comprising cefuroxime axetil |
| 09/19/2001 | EP1133287A2 Use of 17-ketosteroids for the treatment of hepatitis c virus and other togaviruses |
| 09/19/2001 | EP1133280A1 Method of preparing stable suspensions of insoluble microparticles |
| 09/19/2001 | EP0862634B1 Pharmaceutical composition for treating papillomavirus tumours and infection |
| 09/19/2001 | EP0831901B1 Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein |
| 09/19/2001 | EP0772630B1 Streptogramine derivatives, preparation of same and pharmaceutical compositions containing same |
| 09/19/2001 | EP0612244B1 Endothelin receptor antagonists |
| 09/19/2001 | EP0594667B1 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| 09/19/2001 | EP0538297B1 Antiviral tetrahydroimidazo 1,4]benzodiazepin-2-(thio)ones |
| 09/19/2001 | CN1313897A New gene of humanlysoenzyme, the encoding polypeptide and methods for preparing them |
| 09/19/2001 | CN1313864A Particles of HCV envelope proteins use of vaccination |
| 09/19/2001 | CN1313863A Inhibitors of urokinase and blood vessel fomation |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313854A Antiviral pyrimidinedione derivatives and process for the preparation thereof |
| 09/19/2001 | CN1313772A Peptide antagonists of zonulin and methods for use of same |
| 09/19/2001 | CN1313768A Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antivirual agents containing both |
| 09/19/2001 | CN1313766A DNA-cleaving antitumor agents |
| 09/19/2001 | CN1313387A Method for expression various proteins in plants with converted genes |
| 09/19/2001 | CN1313385A Process for preparing genetically engineered efficient medicine target-introduced to human liver cells |
| 09/19/2001 | CN1313343A N-terminal modified protein compositions and methods therefor |
| 09/19/2001 | CN1313284A N-(3-benzofuryl) urea derivative |
| 09/19/2001 | CN1313125A Chinese patent medicine for treating tracheitis and whooping cough and its preparing process |
| 09/19/2001 | CN1313104A Application of liquorice root in preventing and treating AIDS |
| 09/19/2001 | CN1313102A Spray-type gynecological medicine |
| 09/19/2001 | CN1313099A Centipede-snake plaster |
| 09/19/2001 | CN1313098A Shegong powder |
| 09/19/2001 | CN1313090A Quick-acting berberi powder |
| 09/19/2001 | CN1313086A Use of fatty materials for prevention or reduction of microorganism adhere on skin and/or mucous membrane |
| 09/19/2001 | CN1071334C Glycopeptide antibiotic derivatives |
| 09/19/2001 | CN1071331C Anti-helicobacter acyl derivatives of azolones |
| 09/19/2001 | CN1071330C Anti-helicobacter urea and thiourea derivatives of azolones |
| 09/19/2001 | CN1071328C Arginine angalogues having nitric oxide synthase inhibitor activity |
| 09/19/2001 | CN1071128C Process for preparing injection to treat pulmonary tuberculosis |
| 09/18/2001 | USRE37381 Attenuated cdna sequence; genetic engineering; mutants |
| 09/18/2001 | US6291687 Used aspartyl protease inhibitors of human immunodeficiency virus (hiv) |
| 09/18/2001 | US6291670 Viricides against human immunodeficiency virus and aids (acquired immune deficiency syndrome) |
| 09/18/2001 | US6291664 Method of eliminating inhibitory/instability regions of mRNA |
| 09/18/2001 | US6291657 N-butyldeoxygalactonojirimycin; suppression of glycolipid biosynthesis; microbiocides; treatment of gaucher's disease |
| 09/18/2001 | US6291654 Obtaining protein sample from bacteria, applying to solid support of methylamine treated complement protein c3, washing solid support, and removing c3 binding protein from solid support using alcohol solution |
| 09/18/2001 | US6291649 Anti-bodies binding adhesin-derived antigens |
| 09/18/2001 | US6291640 Peptidomimetic inhibitors of the human cytomegalovirus protease |
| 09/18/2001 | US6291518 Hydroxy and polyhydroxy derivatives of coumarin, preparation thereof and antiviral action thereof |
| 09/18/2001 | US6291502 Use of 2-imidazolyl-substituted carbinols for the production of a medicament for the treatment or phophylaxis of diseases caused by ischemic conditions |
| 09/18/2001 | US6291500 Administering an antifungal agent |
| 09/18/2001 | US6291473 Treating anxiety, depression, post-traumatic stress disorder, inflammatory diseases, obesity, in mammals |
| 09/18/2001 | US6291462 Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates |
| 09/18/2001 | US6291457 Compounds having cytokine inhibitory activity |
| 09/18/2001 | US6291448 Carbapenem antibacterial compounds, compositions containing such compounds and method of treatment |
| 09/18/2001 | US6291446 Particularly using the isozyme selective pkc inhibitor, (s)-3,4-(n,n'-1,1'-((2?-ethoxy)-3'?(o)-4'?-(n, n-dimethylamino)-butane)-bis-(3,3'-indolyl))-1(h)-pyrrole-2,5-dione hydrochloride salt. |
| 09/18/2001 | US6291431 Methods and compositions for the treatment and prevention of Staphylococcal infections |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | US6291236 Human cytomegalovirus DNA sequences |
| 09/18/2001 | US6291227 Nucleotide sequences coding viral polypeptides; for use in the development of vaccines which prevent retroviral infections |
| 09/18/2001 | US6291208 Exprsssion vector; for use as diagnostic tools and generating vaccines |
| 09/18/2001 | US6290985 By chewing the gum, the medicament or agent is released from the product. |